Much has been written about new and emerging immuno-oncology targets where we can add new targeted agents to existing immunotherapies – after all, quite a few have already tried and failed in clinical trials to shift the survival curve upwards and to the right.
Can it be done?
I firmly believe so, but this endeavour is going to take the whole field much time and energy, as well as quite a few iterations in molecule and trial design. No one knows what the next big target is though, but when they do it will be a bit like when the boat comes in – you know it when you see it.
In the spotlight today is a relatively obscure target we have written about perhaps once or twice before and now there is suddenly burgeoning interest in this subniche with a couple of players already active in the space. Will there be others? Maybe, it will likely depend on how the phase 1 trials pan out.
We have attempted to cover a couple of key questions:
- What can we learn about the science and research conducted thus far?
- Why is a big biotech company suddenly interested in this target?
- Which tumour types look like being important?
Most importantly, though, a long time reader wrote in and asked why on earth is there sudden interest? Will start a new stampede? Who are the competition?
Good questions, and now we get to set the scene to explain what’s what and why the target matters…